Drugs Prices Control Amendment Order 2026: New Rules on Drug Pricing, Launch Reporting and Compliance

On June 30, 2026, the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers issued Notification S.O. 3516(E), introducing significant amendments to the Drugs (Prices Control) Order, 2013. The amendment order, effective from the date of its publication, establishes new compliance requirements for pharmaceutical manufacturers relating to drug launch intimation, pricing transparency, record retention, and overcharging liability. These changes reshape key aspects of India’s pharmaceutical pricing framework and demand immediate attention from manufacturers, distributors, and compliance teams across the sector.

The 2013 Order has long served as the primary regulatory framework governing drug pricing in India, empowering the NPPA to fix ceiling prices for scheduled drugs and monitor compliance across the supply chain. The 2026 amendment reflects the Government’s continued effort to strengthen oversight while streamlining certain compliance processes. This article examines the key changes, their practical implications, and what pharmaceutical stakeholders should prioritise in their compliance response.

Form IA: New Drug Launch Intimation Process

One of the most notable introductions under the amendment is Form IA, now added to Schedule II of the 2013 Order. This form establishes a structured intimation process for new drug launches. Any manufacturer launching a new drug in India is now required to submit Form IA to the NPPA within one month of the drug’s commercial launch. The form captures essential details about the drug, its formulation, and its proposed retail price, creating a centralised record of market entry. This move toward structured launch reporting mirrors broader regulatory trends across Indian law: for instance, the recent decision where the MCA extends compliance scheme deadline under corporate law similarly reflects the Government’s emphasis on timely and systematic regulatory filings across sectors.

A related provision offers practical relief to manufacturers entering the market after an initial launch by a competitor. Where a new drug has already been launched by one manufacturer and the NPPA has processed the corresponding Form IA filing, any other manufacturer launching the same drug within twelve months of the original launch is exempt from submitting a fresh application for retail price approval. This exemption reduces redundant regulatory processing while ensuring that the pricing framework established by the first entrant provides a benchmark for subsequent market participants.

Revised MRP Communication and Pricing Transparency

The amendment order strengthens the obligations around communication of revised Maximum Retail Prices (MRPs). Manufacturers are now required to circulate updated MRP lists to all dealers and stakeholders within two weeks of any price revision. This tightened timeline ensures that pricing changes are disseminated promptly across the distribution chain, reducing the risk of overcharging at the retail level. The emphasis on pricing transparency in pharmaceutical regulation resonates with broader principles upheld across Indian regulatory frameworks; as illustrated in the case where the Supreme Court on regulatory compliance in mining, Indian courts and regulators have consistently favoured mechanisms that ensure transparent and accountable pricing in regulated industries.

In addition to the distribution requirement, the amendment mandates that manufacturers publish price reduction notices in at least two national newspapers. This dual publication requirement ensures that price reductions receive adequate public visibility, enabling consumers, healthcare providers, and pharmacists to verify that lower prices are being passed through the supply chain. Together, the two-week dealer notification and newspaper publication requirements create a more robust framework for price communication that balances manufacturer obligations with consumer protection.

Record Retention and Paragraph 29

A significant structural addition to the 2013 Order is the insertion of new Paragraph 29, which establishes mandatory record retention requirements for pharmaceutical manufacturers. Under this provision, all records pertaining to drug pricing, production volumes, sales data, and related compliance documentation must be maintained for a period of seven financial years. This creates a clear and enforceable audit trail that the NPPA and other regulatory authorities can rely upon during investigations, compliance reviews, or pricing disputes. The emphasis on long-term record keeping aligns with similar developments in other regulatory frameworks; the recent EPF Scheme 2026 compliance changes, for example, also impose structured documentation and retention requirements on employers under social security legislation.

The seven-year retention period is substantial and signals the Government’s intent to enable retrospective scrutiny of pricing practices over extended periods. Pharmaceutical companies will need to review their internal data management and archival systems to ensure compliance. Companies that currently maintain records for shorter periods, or that rely on fragmented record-keeping systems, face the most urgent need for operational adjustment. Failure to maintain records for the prescribed duration could expose manufacturers to adverse inferences during regulatory proceedings or investigations into pricing irregularities.

Narrowed Overcharging Liability

The amendment order also introduces a nuanced change to the framework governing overcharging liability. Under the revised provisions, liability for overcharging has been narrowed in specified cases, providing greater clarity on when manufacturers may face penalties for selling drugs above the permitted ceiling price. While the 2013 Order has always contained provisions penalising overcharging, the amendment refines the scope of liability to address situations where pricing deviations may have occurred due to transitional factors or regulatory lag rather than deliberate non-compliance. This is a meaningful distinction: it acknowledges that not every instance of a price exceeding the ceiling reflects an intent to overcharge.

This recalibration is significant for manufacturers who have historically faced uncertainty about potential liability during periods of price revision or regulatory transition. By narrowing the circumstances under which overcharging penalties apply, the amendment introduces a degree of proportionality into the enforcement framework. However, this should not be interpreted as a relaxation of pricing discipline: the core prohibition against selling drugs above the ceiling price remains firmly in place, and the NPPA retains broad authority to investigate and penalise genuine instances of overcharging. Manufacturers should view this change as a clarification of boundaries rather than a loosening of standards.

Related Reading

● SEBI amends master circular on client securities

● Consumer forum on product quality standards

Key Takeaways

Pharmaceutical manufacturers must now file Form IA with the NPPA within one month of launching a new drug, establishing a formal intimation process under the amended Drugs (Prices Control) Order, 2013. Manufacturers launching the same new drug within twelve months of the original launch are exempt from filing a fresh retail price application, reducing duplicative compliance burden.

Revised MRP lists must be circulated to dealers within two weeks of any price change, and price reductions must be published in at least two national newspapers. These requirements create tighter timelines for pricing communication and will require operational adjustments in how companies manage and disseminate pricing updates across the pharmaceutical supply chain.

The newly inserted Paragraph 29 requires all pricing, production, and sales records to be maintained for seven financial years, providing regulatory authorities with a long-term audit trail for compliance reviews and investigations. Companies should assess their current data retention practices and upgrade their archival systems where necessary.

While overcharging liability has been narrowed in specified cases to introduce proportionality, the fundamental prohibition against selling drugs above the ceiling price remains intact. Manufacturers should review their compliance frameworks to align with all changes introduced by Notification S.O. 3516(E), effective June 30, 2026, and ensure that internal processes for launch intimation, price communication, and record retention are updated accordingly.